In M-NSCLC patients, the co-existence of a high TMB and neoantigen expression has a positive predictive value of the response to anti-PD1, anti-PD-L1 and anti-CTLA-4 therapy (13, 60). The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.